Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

Aziz, M H, Shen, H, Maki, C G·2011·Oncogene
DOI 10.1038/onc.2011.185

Cited by (133)

Items 101–133 of 133

  1. MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1
    Yanling Chen, Zi-Mu Zhang, Xiaolu Li, Yanfang Tao, Shuiyan Wu, Fang Fang, Yi Xie, Xinmei Liao, Gen Lin Li, Di Wu et al. · 2021 · Oncology Letters
  2. New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics
    Tatyana A. Grigoreva, Aleksandra V. Sagaidak, Daria Novikova, Vyacheslav G. Tribulovich · 2024 · Biomedicines
  3. MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
    Yan Yu Zhu, Herui Wang, Asha Thuraisamy · 2019 · Elsevier eBooks
  4. Understanding p53: new insights into tumor suppression
    Keiko Kawauchi, Steven John Wolf · 2014 · Expert Review of Anticancer Therapy
  5. TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance
    Martin Michaelis, Constanze Schneider, Florian Rothweiler, Tamara Rothenburger, Marco Mernberger, Andrea Nist, Andreas von Deimling, Daniel Speidel, Thorsten Stiewe, Jindrich Jr. Cinatl · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  6. BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition
    Nikolay V. Pervushin, Dmitry K. Nilov, Sergey V. Pushkarev, Victoria O. Shipunova, Бадлаева Алина Станиславовна, Maria A. Yapryntseva, Daria V. Kopytova, Boris Zhivotovsky, Gelina S. Kopeina · 2024 · APOPTOSIS
  7. Long-term cultivation using ineffective MDM2 inhibitor concentrations alters the drug sensitivity profiles of PL21 leukaemia cells
    Martin Michaelis, Florian Rothweiler, Constanze Schneider, Tamara Rothenburger, Marco Mernberger, Andrea Nist, Thorsten Stiewe, Jindrich Jr. Cinatl · 2020 · Experimental Results
  8. Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53
    Iulianna C. Taritsa, Eric T. Fossel · 2025 · Frontiers in Pharmacology
  9. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
    Aline Gottlieb, Kristina Althoff, Laura Grunewald, Theresa Thor, Andrea Odersky, Marc Schulte, Hedwig E. Deubzer, Lukas Carl Heukamp, Angelika Eggert, Alexander R. Schramm et al. · 2017 · Oncotarget
  10. Intact-cell MALDI-ToF mass spectrometry for the authentication of drug-adapted cancer cell lines
    Povey, Jane F., Saintas, Emily, Aderemi, Adewale V., Rothweiler, Florian, Zehner, Richard, Dirks, Wilhelm G., Cinatl, Jindrich, Racher, Andrew J., Wass, Mark N., Smales, C. Mark et al. · 2019 · Cells
  11. Machine learning enhances genotoxicity assessment using MultiFlow ® DNA damage assay
    Panuwat Trairatphisan, Lena Dorsheimer, Peter Monecke, Jan Wenzel, Rubin James, Andreas Czich, Yasmin Dietz, Friedemann Schmidt · 2024 · Environmental and Molecular Mutagenesis
  12. Long transcripts minus touchdown qPCR (LTMT-qPCR): a simplified and convenient method for the screening and quantification of microRNA profile
    Xi Wang, Yixiao Feng, Shixian Zhou, Xiaorong Yang, Yan Liu, Peng Qi, Xuehua Kong, Lan Zhou, Zongyue Zeng · 2021 · Laboratory Investigation
  13. Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
    Anaïs Pujals, Loëtitia Favre, Philippe Gaulard, Joëlle Wiels · 2015 · Blood and Lymphatic Cancer Targets and Therapy
  14. Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer
    Rajakishore Mishra · 2023 · The Applied Biology & Chemistry Journal
  15. Senolytics Target Senescent Cells and Improve Aging and Age-Related Diseases
    Tony Buffard, Gerardo Ferbeyre · 2020 · Healthy ageing and longevity
  16. Targeting p53 Tumor Suppressor for AML Therapy
    Kensuke Kojima, Lyubomir T. Vassilev · 2014 · Springer eBooks
  17. P53 in Head and Neck Squamous Cell Carcinoma
    Janaki Parameswaran, Barbara Ann Burtness · 2018 · Current cancer research
  18. Developing Quinoline-based Secretagogues for Prostate Apoptosis Response-4 Protein (Par-4) as Potential Antineoplastic Agents
    Vitaliy M. Sviripa, Ravshan Burikhanov, Chunming Liu, David S. Watt · 2021 · Springer eBooks
  19. TARGETING THE MDM2-P53 AXIS FOR THE TREATMENT OF DEDIFFERENTIATED LIPOSARCOMA
    Katelynn Bill · 2014 · Digital Commons-TMC (Texas Medical Center)
  20. Surface plasmon resonance and cytotoxicity assays of drug efficacies predicted computationally to inhibit p53/MDM2 interaction
    Xiaoying Wang, Patrycja Magdziarz, Ernest Enriquez, Wang Zhao, Chris Quan, Narek Darabedian, Jamil Antonio Momand, Feimeng Zhou · 2019 · Analytical Biochemistry
  21. In Vivo Discoveries in MDM2-Mediated p53 Regulation
    Nicole R. Tackmann · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  22. Review 1: Long-term cultivation using ineffective MDM2 inhibitor concentrations alters leukaemia cell drug sensitivity profiles
    2019 · Experimental Results
  23. Review 3: Long-term cultivation using ineffective MDM2 inhibitor concentrations alters leukaemia cell drug sensitivity profiles
    2019 · Experimental Results
  24. Review 2: Long-term cultivation using ineffective MDM2 inhibitor concentrations alters leukaemia cell drug sensitivity profiles
    2019 · Experimental Results
  25. Characterization of synthetic lethality between Mdm2 overexpression and genotoxic agents and identification of a novel function of the Mdmx oncogene in DNA repair
    Alexia M. Carrillo · 2014
  26. TP53
    Kensuke Kojima, Michael Andreeff · 2015 · Wiley eBooks
  27. Modulation of HSF1 activity by p53 and its impact in cancer therapies
    Tamara Isermann · 2023
  28. Microglial senescence and senolytic drugs
    Benneth Ben-Azu, Salomé Sabbah, Ifeoluwa Oluleke Awogbindin, Emmanuel Onyinyechukwu Chidebe, Benjamin Oritsemuelebi, Disha Patel, Dan Frenkel, Marie‐Ève Tremblay · 2026 · Elsevier eBooks
  29. Implication de la voie p53 dans les syndromes d'insuffisance médullaire
    Eléonore Toufektchan · 2018 · theses.fr (ABES)
  30. Upregulation of ITM2A by p53 activation modulates p53 function through physical interaction
    Sim Namkoong, Minsu Jang, Jeong In Lee, Siyun Lee, Rackhyun Park, Yangsik Jeong, Eun‐Ju Lee, Junsoo Park · 2026 · Cell Cycle
  31. Hybrid AI-physics screening prioritizes candidate dual MDM2/MDM4 inhibitors from a drug-like library for dedifferentiated liposarcoma
    Solomon Sackitey, Prince Danan Biniyam, Charles Lamptey Mireku, Alberta Hammah, Jesse Ayim Buabeng, Lawrence Kwame Nkrumah, Wise Mawuli Asare, Josephine Frimpomaa Oppong, Emmanuel Gyamfi Obeng, Kwabena Adu-Adjei et al. · 2026 · Research Square
  32. BindingDB Entry 50045594: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    BindingDB · 2016 · UC San Diego
  33. BindingDB Entry 50003121: Role of p53 circuitry in tumorigenesis: A brief review.
    BindingDB · 2020 · UC San Diego